New antiviral treatment could significantly reduce global burden of hepatitis C
Monday, May 6, 2013 - 20:30
in Health & Medicine
Around 150 million people globally are chronically infected with the hepatitis C virus (HCV) -- a major cause of liver disease and the fastest growing cause of liver transplantation and liver cancer. New prevention strategies are urgently required as people are continuing to be infected with HCV. New findings reveal the impact of a new antiviral treatment that could potentially reduce HCV rates in some cities affected by chronic HCV prevalence by half over 15 years.